title: The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992).
abstract: We investigated the activity and toxicity of raltitrexed (Tomudex) as a single agent treatment in patients with Malignant Pleural Mesothelioma (MPM) in a multicentre phase II European Organization for Research and Treatment of Cancer (EORTC) study. This study enrolled chemonaíve patients with histologically-confirmed measurable MPM. Raltitrexed was administered at the dose of 3 mg/m(2) intravenous (i.v.) bolus on an outpatient basis every 3 weeks. A maximum of eight cycles was planned in cases with an absence of progression or unacceptable toxicity. 24 patients received a total of 104 courses. 5 patients (20.8%, 95% confidence interval (CI) 7.1-42.2%) had a partial response (PR), which was confirmed by an independent radiology committee. Toxicity was mild, with diarrhoea, nausea, vomiting, fatigue and neutropenia as the major side-effects, but not exceeding grade 3 toxicity. We conclude that raltitrexed has activity as a single agent in the treatment of MPM, and that further studies with this drug in MPM are warranted.
authors.affiliation: The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. p.baas@nki.nl
authors.forename: P
authors.initials: P
authors.lastname: Baas
authors.forename: A
authors.initials: A
authors.lastname: Ardizzoni
authors.forename: F
authors.initials: F
authors.lastname: Grossi
authors.forename: K
authors.initials: K
authors.lastname: Nackaerts
authors.forename: G
authors.initials: G
authors.lastname: Numico
authors.forename: E
authors.initials: E
authors.lastname: Van Marck
authors.forename: M
authors.initials: M
authors.lastname: van de Vijver
authors.forename: F
authors.initials: F
authors.lastname: Monetti
authors.forename: M J A
authors.initials: MJ
authors.lastname: Smid-Geirnaerdt
authors.forename: N
authors.initials: N
authors.lastname: van Zandwijk
authors.forename: C
authors.initials: C
authors.lastname: Debruyne
authors.forename: C
authors.initials: C
authors.lastname: Legrand
authors.forename: G
authors.initials: G
authors.lastname: Giaccone
mesh_terms: D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008654:Mesothelioma / Q000188:drug therapy*; D008875:Middle Aged; D010997:Pleural Neoplasms / Q000188:drug therapy*; D011799:Quinazolines / Q000008:administration & dosage* / Q000009:adverse effects; D012189:Retrospective Studies; D016019:Survival Analysis; D013876:Thiophenes / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D000964:Antimetabolites, Antineoplastic; D011799:Quinazolines; D013876:Thiophenes; C068874:raltitrexed